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Recent advances enabling the cloning of human
immunoglobulin G genes have proven effective
for discovering monoclonal antibodies with thera-
peutic potential. However, these antibody-discovery
methods are often arduous and identify only a few
candidates from numerous antibody-secreting
plasma cells or plasmablasts. We describe an in vivo
enrichment technique that identifies broadly neutral-
izing human antibodies with high frequency. For this
technique, human peripheral blood mononuclear
cells from vaccinated donors are activated and
enriched in an antigen-specific manner for the pro-
duction of numerous antigen-specific plasmablasts.
Using this technology, we identified four broadly
neutralizing influenza A antibodies by screening
only 840 human antibodies. Two of these antibodies
neutralize every influenza A human isolate tested and
perform better than the current anti-influenza A ther-
apeutic, oseltamivir, in treating severe influenza
infection in mice and ferrets. Furthermore, these an-
tibodies elicit robust in vivo synergism when com-
bined with oseltamivir, thus highlighting treatment
strategies that could benefit influenza-infected pa-
tients.
INTRODUCTION
Each year in the United States, 5% to 20% of the population be-
comes infected with influenza, and the majority of these infec-
tions are caused by the influenza A virus (Thompson et al.,
2003; Thompson et al., 2004; Dushoff et al., 2006). Even with
broad use of the anti-influenza drug oseltamivir phosphate (Ta-
miflu), approximately 200,000 people become hospitalized with
influenza-related complications, culminating in 7,000 to 30,000Cedeaths annually (Thompson et al., 2003; Thompson et al.,
2004; Dushoff et al., 2006). Beyond causing significant seasonal
mortality, influenza A has the potential to cause worldwide pan-
demics, making the discovery of novel influenza A therapeutics
imperative (Fraser et al., 2009).
Influenza A is a membrane-enveloped RNA virus that ex-
presses two immunodominant surface proteins, hemagglutinin
(HA) and neuraminidase (Bouvier and Palese 2008). HA pro-
motes viral attachment and entry into the host cell, whereas
neuraminidase is required for efficient viral budding from the in-
fected cell (Wiley and Skehel 1987; Bouvier and Palese 2008).
The majority of neutralizing antibodies generated during a
normal immune response target HA and block viral entry (Wiley
and Skehel 1987). However, significant sequence diversity
among HA genes limits the broad protection of these antibodies.
This sequence diversity is represented by 17 HA serotypes that
align into twomajor groups called group 1 (Grp1), which includes
H1, H2, and H5, and group 2 (Grp2), which includes H3 and H7.
The HA subtypes associated with human disease are typically
limited to H1, H2, and H3, whereas viruses encoding H5 and
H7 only cause sporadic human outbreaks with no sustained hu-
man-to-human transmission.
Oseltamivir phosphate is a widely used prophylactic and early
therapeutic treatment option for influenza A infection (Nicholson
et al., 2000; Treanor et al., 2000; Kandel and Hartshorn 2001;
Welliver et al., 2001). However, oseltamivir treatment must begin
within 48 hr of symptom onset to provide the most robust clinical
benefit (Aoki et al., 2003). This compromises oseltamivir’s ability
to treat severely ill patients, who are typically beyond the optimal
48 hr treatment window. Additionally, oseltamivir resistance has
been confirmed in many human influenza isolates. Therefore,
significant focus has recently been placed on identifying influ-
enza therapeutics for treating hospitalized patients with influenza
and for circumventing oseltamivir resistance. One strategy has
focused on the development of human monoclonal antibodies
(mAbs) that target a highly conserved epitope on the stalk of
influenza A HA (Ekiert et al., 2009; Sui et al., 2009; Corti et al.,
2011; Ekiert et al., 2011; Dreyfus et al., 2012). Indeed, several
studies have described mAbs that bind to this epitope andll Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc. 93
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has been described that can engage this epitope and neutralize
all human influenza isolates from Grp1 and Grp2. Specifically,
Corti et al. (2011) described the FI6v3 mAb, which was cloned
from a human plasma cell and can neutralize all human influenza
viruses belonging to both Grp1 and Grp2 HA subtypes. The
FI6v3 mAb was discovered as a result of a massive effort of
analyzing approximately 104,000 in-vitro-cultured human
plasma cells for the identification of one antibody with this large
breadth of potency (Corti et al., 2011). This low identification
frequency suggests the rarity of Grp1- and Grp2-neutralizing an-
tibodies within the human immune repertoire. Indeed, several
previous reports have shown the inability to discover such anti-
bodies from human-derived phage-display libraries (Ekiert
et al., 2009; Sui et al., 2009; Ekiert et al., 2011; Dreyfus et al.,
2012). This observation is exemplified by another recent report
that describes the antibody CR9114, which is able to neutralize
some influenza strains within Grp1 and Grp2 but is unable to
bind or neutralize virus strains carrying the H2 HA subtype (Drey-
fus et al., 2012). Therefore, we set out to develop a technique that
could enrich for rare antigen-specific human plasmablasts that
produce antibodies capable of binding and neutralizing H1,
H2, H3, H5, and H7 subtypes of influenza A.
Here, we describe an in vivo antigen-driven enrichment tech-
nique wherein human peripheral blood mononuclear cells
(hPBMCs) obtained from vaccinated normal human donors
were activated and enriched in an antigen-specific manner for
the production of large numbers of antigen-specific plasma-
blasts. This technique allowed high-frequency identification of
broadly neutralizing influenza antibodies without the need for
plasma cell propagation or generation of phage-display libraries.
Two of these mAbs, 39.29 and 81.39, are capable of neutralizing
all human influenza isolates within Grp1 and Grp2 influenza A.
The 39.29 mAb exhibits superior therapeutic efficacy when
compared to oseltamivir in mouse and ferret influenza A infection
models. We have also discovered that coadministration of a sub-
efficacious dose of the 39.29 mAb in combination with oseltami-
vir is significantly more protective than either agent alone in a
mouse infection model. Importantly, this in vivo antigen enrich-
ment technique allowed us to identify these rare antibodies by
cloning only 840 immunoglobulin G (IgG) heavy- and light-chain
gene pairs. This is in contrast to several influenza-antibody dis-
covery efforts, which have in total yielded only one such anti-
body, FI6v3 (Corti et al., 2011).
RESULTS
Enrichment of Antigen-Specific Plasmablasts In Vivo
within Human-SCID Chimeras
The discovery of the scid mutation over three decades ago has
allowed a wide variety of short- and long-term xenogeneic chi-
meras when human hematopoietic cells are transferred to these
immunodeficient hosts (Bosma et al., 1983; Depraetere et al.,
2001). Consistent with previous reports, the intrasplenic trans-
plantation of hPBMCs into the severe combined immunodefi-
ciency (SCID)/beige recipients allowed for rapid expansion and
B cell activation, resulting in their differentiation into human plas-
mablasts (Depraetere et al., 2001) (Figure 1A). Specifically, we
found that human plasmablasts expanded to a large proportion94 Cell Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc(23.87% ± 9%) of the total splenic cell population 8 days after
transplantation of hPBMCs (data not shown). Of these,
18.7% ± 6% were IgG+ plasmablasts, as compared to only
0.13% ± 0.12% prior to transplantation (Figure 1B, left panels).
To determine whether this process could be utilized to enrich
for plasmablasts that are specific for a single antigen, we pre-
mixed PBMCs from tetanus-diphtheria (TD)-vaccinated human
donors in vitro with Tetanus toxoid (TT) prior to intrasplenic injec-
tion of the SCID/beige recipients. This technique resulted in an
18- to 20-fold enrichment in frequency of plasmablasts that
produce TT bindingmAbs as compared to the input PBMCs prior
to SCID transplantation (Figure 1B, right panels). Specifically,
only 1 out of every 1,300 plasmablasts from the vaccinated
donor stained positive for TT prior to the SCID transplantation.
However, after the SCID enrichment technique, 1 out of every
75 plasmablasts was making IgG specific for TT. To optimize
the in vivo enrichment technique, we compared the frequencies
of TT-specific plasmablasts before and after human-SCID
(hSCID) enrichment under various in vitro and in vivo stimulation
conditions. Specifically, we tested a combination of conditions
including in vitro TT antigen premix, in vivo antigen boost, and
a cocktail of plasmablastotrophic cytokines (B cell activating
factor [BAFF], interleukin-2 [IL-2], IL-6, and IL-21) (Figure 1C)
(Klein et al., 2003). This comparison showed that in vitro antigen
premix resulted in the best in vivo enrichment of TT-positive
plasmablasts irrespective of cytokine stimulation (Figure 1C).
In Vivo Enrichment of Influenza Grp1 and Grp2 Broadly
Reactive Human Plasmablasts in hSCID Chimeras
We next applied the hSCID enrichment technique to obtain large
numbers of mAbs that were highly reactive to diverse HA
subtypes across Grp1 and Grp2 influenza A strains (Figure 2A).
Specifically, the hPBMC donor was vaccinated with the Fluvirin
vaccine from Novartis, which contained influenza A HA proteins
from the H3N2 A/Perth/16/2009 strain and the H1N1 A/Califor-
nia/7/2009 strain. We used HA variants distinct from the vaccine
for in vitro antigen premix and cell sorting to select for cells pro-
ducing antibodies specific to highly conserved HA epitopes (Fig-
ure 2A). Finally, the cloned antibodies were screened for binding
to HA variants that differed from those used in the vaccine and
expansion technique, such as H5 from A/Vietnam/1203/2004
and H1 from A/South Carolina/1/1918 (Figure 2A). It should be
noted that for increasing the likelihood of identifying antibodies
that bind to highly conserved HA epitopes, the HA variants
used for all steps downstream of the vaccination were carefully
selected for encompassing the natural diversity within human
influenza A.
Similarly to the tetanus-antigen premix studies, intracellular
IgG+ plasmablasts reactive to HA H1 from A/WSN/1933 were
robustly detected in SCID mice that received vaccinated
hPBMCs that had undergone HA antigen premix prior to intra-
splenic transplant (Figure 2B). The frequency of cells that could
bind to both H1 and H3 variants was increased over 150-fold
in the hSCID mice as compared to the input PBMCs derived
from vaccinated donors (Figure 2C). These findings indicate
that in vitro premix of the HA cocktail with primed PBMCs from
influenza-vaccinated donors promoted the enrichment of anti-
gen-specific plasmablasts within the SCID/beige mice to pro-
duce antibodies capable of binding a diverse set of HA subtypes..
Figure 1. In Vivo Enrichment of Antigen-
Specific Human Plasmablasts in hSCID Chi-
meras
(A) Scheme of in vivo antigen (Ag)-driven plasma-
blast differentiation in hSCID chimeras.
(B) Representative fluorescence-activated cell
sorting (FACS) data showing hPBMCs obtained
from TD-vaccinated normal human donors at
7 days post vaccine (top panels) or splenocyte
profiles at day 8 after hSCID enrichment (bottom
panels). Right panels show frequencies of intra-
cellular IgG+TT+ plasmablasts from either input
PBMCs (top panel, mean ± SEM, n = 4 donors) or
hSCID splenocytes under TT antigen premix con-
ditions (bottom panel, mean ± SEM, n = 40 mice).
(C) Frequency of TT-specific plasmablasts
recovered from splenocytes of hSCID chimeras
under various stimulation conditions. The in vivo
boost contained 100 mg TT injected intraperito-
neally into hSCID mice on day 2 after trans-
plantation. The cytokine cocktail contained a
mixture of human BAFF (50 mg) and human IL-2,
IL-6, and IL-21 at 50 ng each, injected intraperi-
toneally to hSCID mice on days 1, 4, and 7 after
transplantation. The plot is expressed as the fold
increase of frequency over input PBMCs. One TD-
vaccinated human-donor PBMC sample was
used to repopulated batches of SCID/beige mice;
n = 7 mice/group, n = 42 per study. The * indicates
p > 0.05; Dunnett’s multiple-comparison test
versus the cells-only control group.
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studies that only a fraction of transplanted mice presented the
desired antigen-specific plasmablasts after in vivo enrichment
(Figure 2B). This indicates the stochastic nature of this process
and underscores the importance of using large cohorts of mice
to enrich for the desired plasmablasts from even a single vacci-
nated donor PBMC pool.
We isolated 950 plasmablasts that demonstrated H1 and H3
cross-reactivity by single-cell sorting (Figure 2C; Table S1 avail-
able online). Heavy- and light-chain genes encoding each IgG
were cloned and expressed transiently in 293S cells, resulting
in approximately 840 plasmablast-derived mAbs (Table S1).
These mAbs were then screened by ELISA for binding to H1,
H5, H3, and H7 HA subtypes, which yielded 82mAbs that bound
to an HA variant distinct fromHA found within the vaccine and 20
mAbs that bound all HA subtypes tested (Table S1). It should be
stressed that this screening technique was not meant to investi-
gate the effectiveness of the vaccine bymeasuring the frequencyCell Host & Microbe 14, 93of antibodies that could recognize the
vaccine HA variants, but instead to iden-
tify those antibodies capable of binding
to highly conserved epitopes across
many HA subtypes.
Each antibody with broad HA binding
capability was tested for in vitro neutrali-
zation against a panel of human Grp1
and Grp2 influenza A isolates. Four anti-
bodies exhibited potent neutralization ac-
tivity that falls into three neutralizationclasses: Grp1 specific, Grp2 specific, or Grp1/2 specific (Table
1). The 39.18 antibody neutralized all human Grp1 influenza A
strains tested, whereas 36.89 neutralized all human Grp2 influ-
enza A strains tested. Importantly, the 39.29 and 81.39 mAbs
were able to neutralize all human influenza A isolates tested,
which included seasonal H1N1, H3N2, and H2N2 isolates across
Grp1 and Grp2 (Table 1). Also, 39.29 neutralized an equine H7N7
virus and a pseudotyped virus expressing the H5 HA subtype
(Figure S1). Future work will be needed to assess 39.29 and
81.39 binding and neutralization of the remaining 17 HA sub-
types. Nonetheless, the hSCID expansion and antigen-specific
sorting allowed for the rapid identification of four broadly neutral-
izing influenza A antibodies through the screening of app-
roximately 950 human-antibody-producing cells, an increase in
efficiency of approximately 100-fold over the previously
described technique(Corti et al., 2011).
The germline usage of the broadly neutralizing mAbs for both
the variable heavy and variable light chains was unique to each–103, July 17, 2013 ª2013 Elsevier Inc. 95
Figure 2. In Vivo Enrichment of Influenza A
HA H1 and HA H3 Double-Reactive Human
Plasmablasts in hSCID Chimeras
(A) Schematic showing a phylogenetic tree of
the influenza A HA subtypes used during vacci-
nation, premix, single-cell sorting, and binding
studies.
(B) Frequency of HA H1 WSN reactive plasma-
blasts recovered from splenocytes of hSCID
chimeras 8 days after transplantation. The plot is
expressed as the fold increase in frequency of A/
WSN/1933 H1 HA binding plasmablasts over input
PBMCs prior to the hSCID injection. Human
PBMCs from a single influenza-vaccinated donor
were used to repopulate all SCID/beige mice.
There were n = 10 mice/group in the no-antigen
premix and n = 30 mice/group in the antigen pre-
mix condition. The blue rectangle indicates mice
that presented positive A/WSN/1933 HA H1 reac-
tive plasmablasts.
(C) Representative FACS profiles showing fre-
quencies of plasmablasts capable of binding to HA
from A/WSN/1933 and HA from A/Hong Kong/
1968 for seasonal-flu-vaccinated donors’ PBMCs
(top panels) or from splenocytes recovered from
hSCID chimeras at day 8 after antigen premix and
intrasplenic transplantation (bottom panels). Fre-
quency calculations are based on themean ± SEM
of 12 human vaccinated donor PBMC isolates and
splenocytes from 50 hSCID mice after expansion.
See also Figure S1 and Table S1.
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IGHV1-69*01 and IGKV3-15*01 germlines, whereas the Grp2-
specific 36.89 antibody uses IGHV1-18*01 and IGKV1-5*0. The
Grp1/2-specific 39.29 and 81.39 antibodies utilize the IGHV3-
30*01 and IGKV3-15*01 germlines. The heavy- and light-chain
sequences of all four antibodies contain somatic mutations in
the framework and complementarity-determining regions
(CDRs) indicative of antibody maturation that follows repeated
antigen exposure. The number of mutations observed for each
antibody averages 13 variable heavy-chain and 8 variable light-
chain somatic mutations. The 39.18 mAb has 10 variable heavy-
and 5 variable light-chain mutations, whereas 36.89 has 15
variable heavy- and 9 variable light-chain mutations, the majority
of which are found in CDRs. The 39.29 mAb has 12 variable
heavy- and 9 variable light-chain mutations, whereas the 81.39
mAb contains 15 heavy- and 7 light-chain mutations.96 Cell Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc.Structural Characterization of the
39.29 Epitope on H3 HA
To understand the structural basis for HA
neutralization, we crystallized and deter-
mined the structure at 3.1 A˚ of the 39.29
Fab fragment in complex with HA from
an H3N2 influenza A isolate, A/Perth/16/
2009 (Figure 3A). The overall structure of
the Perth H3 HA is similar to previously
determined HA structures. We observed
slight head-group rearrangements and
disorder near the HA2 B-loop, which
have been seen previously under similarlow-pH crystallization conditions (Ekiert et al., 2011; Xu and Wil-
son 2011).
In our structure, we found a single 39.29 Fab molecule bound
to each monomer of the uncleaved H3 HA trimer (Figure 3A).
Both the light-chain and heavy-chain fragments of 39.29 variable
regions were well resolved (Figure S2), allowing close examina-
tion of the HA interaction (Figure 3B). The 39.29 epitope lies on
the stalk region of the H3 HA, roughly on top of the HA2 helix
A. This region of the HA stalk was first identified as a broadly
neutralizing epitope for viruses expressing Grp1 HA subtypes
(Okuno et al., 1993; Ekiert et al., 2009; Sui et al., 2009), and
more recently as a neutralizing epitope for influenza strains car-
rying Grp1 and Grp2 HA subtypes (Corti et al., 2011; Dreyfus
et al., 2012). The 39.29 antibody uses extensive heavy- and
light-chain contacts to bury approximately 1,175 A˚2 of the HA-
stalk surface area. The heavy chain contributes to binding largely
Table 1. In Vitro Neutralization Data
Influenza Strain HA Subtype
39.18 39.29 81.39 36.89
IC50 (nM) 95% CI (nM) IC50 (nM) 95% CI (nM) IC50 (nM) 95% CI (nM) IC50 (nM) 95% CI (nM)
A/California/7/2009 H1 1.1 0.75–1.6 2.5 2.0–3.1 2.1 1.1–3.8 >1,600 NA
A/Brisbane/59/2007 H1 2.3 1.8–3.0 1.9 1.2–2.9 0.65 0.46–0.94 >1,600 NA
A/Solomon/3/2006 H1 8.0 3.9–16.6 25.1 20.1–31.4 14.6 12.3–17.4 >1,600 NA
A/New Caledonia/20/1999 H1 3.1 1.3–7.4 9.2 5.7–15.0 6.1 4.7–7.9 >1,600 NA
A/PR/8/1934 H1 1.2 0.81–1.9 2.0 1.3–3.3 1.9 1.2–3.2 >1,600 NA
A/Japan/305/1957 H2 2.4 1.4–4.1 6.0 4.4–8.1 3.7 2.4–5.6 >1,600 NA
A/Victoria/361/2011 H3 >1,600 NA 3.4 2.4–4.8 3.6 2.4–5.3 9.7 8.0–11.9
A/Perth/16/2009 H3 >1,600 NA 3.0 2.4–3.8 1.6 1.2–2.0 1.1 0.86–1.5
A/Brisbane/10/2007 H3 >1,600 NA 2.3 2.0–2.7 1.9 1.7–2.2 1.9 1.5–2.4
A/Wisconsin/67/2005 H3 >1,600 NA 1.3 0.88–1.8 0.81 0.64–1.0 1.6 0.81–3.3
A/Victoria/3/1975 H3 >1,600 NA 2.5 1.9–3.4 2.8 2.2–3.7 2.2 0.94–5.0
A/Port Chalmers/1/1973 H3 >1,600 NA 2.2 1.6–3.1 1.5 1.1–1.9 1.9 0.75–4.6
A/Hong Kong/8/1968 H3 >1,600 NA 45.1 25.7–79.2 26.3 14.5–47.8 34.7 19.8–60.7
A/Aichi/2/1968 H3 >1,600 NA 35.0 21.1–58.0 7.3 3.7–14.1 13.9 8.2–23.4
The abbreviations used in the table are as follows: HA, hemagglutinin; IC50, half-maximal inhibitory concentration; CI, confidence interval; and NA, did
not neutralize.
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shallow nonpolar groove adjacent to HA2 helix A and underneath
a conserved Grp2 HA glycosylation site at Asn54, which is re-
ported to impede the binding of the Grp1-specific influenza A an-
tibodies (Throsby et al., 2008; Ekiert et al., 2009; Sui et al., 2009;
Ekiert et al., 2011). Specifically, this CDRH3 loop extends the
Phe99 side chain out to interact with H3 HA Thr334, Ile390,
and Ile393 while making main-chain polar contacts with the
GlcNAc attached to Asn54. In addition, the 39.29 light chain con-
tributes significantly to binding of the H3 HA stalk epitope, ac-
counting for 60% of the total buried surface area (Figures 3C
and 4A). The 39.29 light chain makes contacts via all three
light-chain CDR loops, with polar contacts formed between
light-chain residues Asn32, Ser52, and Asn93 and HA2 helix A.
This large dependence on light-chain contacts is specific to
the antibodies that can neutralize all isolates within Grp1 and
Grp2. For example, the previously reported Grp1/2 antibody
FI6v3 also uses light-chain contacts to contribute 20% of the
buried surface area (Figure 4C) (Corti et al., 2011). In contrast,
the CR9114 antibody, which is unable to engage the H2 HA sub-
type, does not make any light-chain contact with the HA-stalk
epitope (Figure 4C) (Corti et al., 2011; Dreyfus et al., 2012). Addi-
tionally, crystal-structure analysis of the previously published
Grp1-specific antibodies (F10 and CR6261) and the Grp2-spe-
cific antibody (CR8020) shows that they engage the HA-stalk
epitope using only heavy-chain contributions (Ekiert et al.,
2009; Sui et al., 2009; Ekiert et al., 2011). Comparison of the
39.29, FI6v3, and CR9114 structures in complex with HA re-
vealed that all three antibodies bind an epitope that includes
the HA2 helix A and adjacent nonpolar groove (Figures 4A–4C).
However, each of the three antibodies has a unique binding
orientation; each heavy chain is bound to a similar topographical
position on HA, but light-chain positioning is rotated by 60
(FI6v3) or 120 (CR9114) compared to 39.29. Also unique to
39.29, the IgKV3 light chain SGSGSG repeat in the b strand 6
framework makes contact with the H3 HA. Therefore, the 39.29Cestructure represents a third solution to binding this highly
conserved epitope and shows the importance of engaging the
HA2 helix A for broad neutralization of influenza A. Additionally,
it highlights the potential importance of light-chain contacts for
the ability to neutralize all of the Grp1 and Grp2 influenza A iso-
lates that can infect humans.
Utilizing a competition ELISA assay, we established that the
39.29, 81.39, 39.18, and 36.89 antibodies all compete for over-
lapping regions of the HA-stalk epitope (Figure S3). Specifically,
the 81.39 and 39.18 antibodies could compete for binding of
39.29 on the stalk of H1 HA, whereas the 81.39 and 36.89 anti-
bodies compete for binding with 39.29 for the identified stalk
epitope of H3 HA (Figures S3A–S3C). To compare the 39.29
H3 HA contact residues identified by X-ray crystallography
with other HA subtypes, we aligned H3 HA with representative
H1, H2, H5, and H7 HA sequences, which shows a clear
sequence conservation among the contact residues that
contribute maximally to binding of 39.29 (Figure S3D marked
with asterisks). These data suggest that each broadly neutral-
izing antibody identified in this report potentially binds an epitope
shared at least in part by 39.29.
In Vivo Efficacy of 39.29 in Mice
We tested the in vivo efficacy of 39.29 against four different influ-
enza A isolates that exhibited a range of in vitro half-maximal
inhibitory concentration (IC50) values (Table 1). Mice were chal-
lenged with a minimum lethal intranasal dose of A/PR/8/1934
H1N1, A/Hong Kong/1/1968 H3N2, A/Port Chalmers/1/1973
H3N2, or A/Aichi/2/1968 H3N2. The infection was allowed to
progress 72 hr before intravenous (i.v.) administration of 39.29.
Independent of the influenza strain used for infection, control
IgG-treated animals exhibited 100% mortality by days 11 to 14
(Figures 5A–5D). A single 900 mg i.v. dose (45 mg/kg) of 39.29
was highly efficacious, showing 100% protection in each mouse
model. Single 300 mg (15 mg/kg) and 100 mg (5 mg/kg) i.v.
doses were also 100% protective in the Aichi and Port Chalmersll Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc. 97
Figure 3. Crystal Structure of 39.29 Fab in
Complex with H3 HA
(A) Overview of the structure of the A/Perth/16/
2009 H3 HA in complex with the 39.29 Fab. The
39.29 light chain (VL) is shown in cyan, 39.29 heavy
chain (VH) in yellow, HA1 ‘‘head’’ domain in blue,
and the HA2 ‘‘stalk’’ domain in red. Modeled HA
glycan residues are shown as blue spheres.
(B) Detailed views of the 39.29 VL contacts
(left panel) and VH contacts (right panel) with the
H3 HA stalk. Interacting residues are shown as
sticks, and polar contacts are drawn as dashed
blue lines.
(C) Surface representation of the H3 HA stalk
showing residues contacted (<4.5 A˚) by the 39.29
VL (cyan), VH (yellow), or both chains (magenta).
See also Figure S2 and Table S5.
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PR8models. However, all tested doses provided significant pro-
tection compared to the control-treated animals (Figures 5A–5D).
Consistent with the survival benefit, 39.29-treated mice that sur-
vived the infection were able to regain 100% of their preinfection
body weight before the end of the study (Figure S4). These data
demonstrate the therapeutic potential of 39.29 in Grp1 and Grp2
influenza A mouse infection models and provide evidence that
little correlation exists between the in vitro IC50 values and the
minimum in vivo efficacious dose. Specifically, 39.29 has similar
IC50 values of 2.0 nMand 2.2 nMagainst the PuertoRico andPort
Chalmers models, respectively, yet a single 100 mg dose is fully
protective in the Port Chalmers model but only 40% protective
against the Puerto Rico strain (Table 1; Figures 5A and 5B).
Likewise, the 39.29 mAb has a 10-fold-higher in vitro IC50 value
against Aichi (35 nM) than against Puerto Rico (2 nM), yet all
doses offer 100% protection in the Aichi model (Figures 5A and
5D). It is possible that in vivo viral growth kinetics and host
immune-response differences in the four influenza A models
accounts for this effect. Consistent with this observation, a lack
of correlation between in vitro potency and in vivo efficacy has
also been described for neutralizing antibodies of the vesicular
stomatitis virus (Bachmann et al., 1997).
Antibody Treatment Is Superior to Oseltamivir in Mouse
and Ferret Influenza A Models
Prophylactic administration of oseltamivir is effective at curbing
human influenza A infection if given within 48 hr after symptom
onset. However, oseltamivir has a reduced benefit in patients
that have been symptomatic for more than 48 hr. In an effort to
mimic the latter scenario in our mouse influenza A model, mice
were infected with a high dose of PR8 for 48 hr prior to treatment.
Control-IgG-treated animals showed 100% mortality by 9 days
post infection (Figure 6A). An oseltamivir regimen consisting of98 Cell Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc.2 mg (100 mg/kg) dosed twice daily
(b.i.d.) for 5 days was compared with a
single 300 mg i.v. dose (15 mg/kg) of
39.29. As expected, oseltamivir treatment
only protected 37.5% of mice from
lethality, whereas the single dose of
39.29 resulted in an 87.5% survival (Fig-ure 6A). Also, mice treated with 39.29 consistently regained their
body weight faster than oseltamivir-treated mice (Figure S5A).
We next tested the in vivo efficacy of 39.29 and 81.39 against
the highly pathogenic A/Vietnam/1204/2004 H5N1 virus in fer-
rets, which are considered a clinically relevant animal model
for human influenza infection (Matsuoka et al., 2009). Ferrets
were challenged with a lethal intranasal dose of virus, and then
given a single 25 mg/kg i.v. dose of either control IgG, 39.29
mAb, or 81.39 mAb at 48 or 72 hr post infection. Survival was
compared to animals receiving a 5 day b.i.d. regimen of oral
oseltamivir at 25 mg/kg starting at 48 or 72 hr post infection.
Consistent with H5N1 infection, the majority of infected ferrets
showed early signs of upper respiratory disease by 48 hr post
infection. By 14 days post inoculation, the control IgG antibody
treatment group exhibited 90%mortality (Figure 6B). In contrast,
animals that received 39.29 at 48 and 72 hr post infection
showed 80% and 90% survival, respectively (Figure 6B). Like-
wise, ferrets receiving 81.39 at 48 and 72 hr post infection
showed 100% and 80% survival, respectively (Figure S5B). Irre-
spective of the treatment-initiation time, the oseltamivir-treated
groups showed 50% mortality. We conclude that the broadly
neutralizing influenza A antibodies are highly protective in the
treatment of severe H5N1 infection in ferrets and perform better
than oseltamivir when administered at 48 and 72 hr post
infection.
The Synergistic In Vivo Effect of 39.29 and Oseltamivir
Despite the reduced efficacy of oseltamivir if given 48 hr post
symptom onset, we anticipate that a proportion of severe-influ-
enza-infected patients will be prescribed an oseltamivir regimen
upon hospital admission. Therefore, we tested whether coad-
ministration of 39.29 and oseltamivir improves efficacy over
either treatment alone. To test this hypothesis, mice were in-
fected with a high lethal dose of PR8 and treated at 72 hr post
Figure 4. Comparison of the 39.29, FI6v3,
and CR9114 Epitopes on HA
The HA surface representation shows heavy-chain
(yellow) and light-chain (green) contact atoms
within 4.5 A˚. For the inset figures, heavy-chain
CDRs are shown in yellow, and light-chain CDRs
are shown in green. HA2 helix A is labeled for
orientation.
(A) The epitope for 39.29 bound to 2009/Perth/H3.
(B) The epitopes for FI6v3 bound to 1968/Aichi/H3
(PDB ID code: 3ZTJ) and FI6v3 bound to 2009/
California/H1 (PDB ID code: 3ZTN)(Corti et al.,
2011).
(C) The epitope for CR9114 bound to 2004/Viet-
nam/H5 (PDB ID code: 4FQI)(Dreyfus et al., 2012).
See also Figure S3.
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dose of 100 mg of 39.29 (5 mg/kg), a 2 mg (100 mg/kg)
b.i.d. oral dose of oseltamivir for 5 days, or a combination of
these two therapies. As expected, control-IgG-treated animals
exhibited 100% mortality 9 days post infection (Figure 6C). The
mortality observed for control-treated animals was very similar
to that of the groups receiving only oseltamivir or a subeffica-
cious dose of 39.29. However, the coadministration of 39.29
plus oseltamivir significantly improved the outcome over either
treatment alone, resulting in 87.5% survival (Figure 6C). Consis-
tent with the survival benefit, mice treated with a combination of
39.29 and oseltamivir were able to regain their body weight to
90%of their preinfection body weight before the end of the study
(Figure S5C).
DISCUSSION
In this studywe present amethod for the efficient identification of
very rare functional mAbs. This method consists of antigen-spe-
cific in vivo plasmablast enrichment followed by antigen-specific
single-cell sorting, IgG cloning, and functional characterization
of the candidate mAbs. The conditions for optimizing the in vivo
hSCID enrichment were established using the TT antigen and
then applied for enriching for rare broadly binding influenza A
antibodies that could neutralize all Grp1 and Grp2 human influ-
enza A isolates. This report describes the identification of anti-
bodies that can neutralize all human strains within Grp1 and
Grp2 influenza A. Another described antibody of this type,
FI6v3, was discovered as a result of analyzing approximately
104,000 in-vitro-cultured human plasma cells to discover a sin-
gle antibody that could neutralize all human influenza A strains
(Corti et al., 2011). Several previous studies have been published
describing the isolation of broadly neutralizing influenza A anti-
bodies. However, these studies often used phage-display tech-Cell Host & Microbe 14, 93nology to identify antibodies that cannot
neutralize all human influenza A isolates
(Ekiert et al., 2009; Sui et al., 2009; Ekiert
et al., 2011; Dreyfus et al., 2012). Addi-
tionally, the recently described CR9114
antibody has the ability to neutralize influ-
enza A isolates across Grp1 and Grp2,
yet fails to bind the H2 HA subtype (Drey-fus et al., 2012). In contrast, the enrichment strategy described
here allowed the identification of two group-specific antibodies,
39.18 and 36.89, and two Grp1/2-specific antibodies, 39.29 and
81.39, by screening only 840 cloned human antibodies.
All four broadly neutralizing antibodies identified in this
study are derived from a single donor and bind an overlapping
epitope on the HA stalk. The antibodies fall into three different
neutralization classes, Grp1 specific, Grp2 specific, and
Grp1/2 specific, and each neutralization class is represented
by a different heavy-chain germline. The Grp1-specific anti-
body, 39.18, uses the IGHV1-69*01 germline. This is the same
heavy-chain germline used by several other reported Grp1-spe-
cific neutralizing antibodies, namely A66, F10, and CR6261
(Ekiert et al., 2009; Sui et al., 2009). This is in agreement with
a recent report that shows that the naive IGHV1-69 germline
has an initial affinity toward the Grp1 HA family members and
is therefore selected for future hypersomatic mutation, which
drives affinity toward this highly conserved epitope on Grp1
HA variants (Lingwood et al., 2012). The identified Grp2-specific
antibody, 36.89, uses the IGHV1-18*01 germline, which is the
same heavy-chain germline used by the previously described
Grp2-specific antibody, CR8020 (Ekiert et al., 2011). Addition-
ally, the two identified Grp1/2-specific antibodies, 39.29 and
81.39, have related heavy- and light-chain CDR sequences,
suggesting that they probably originate from the same initial B
cell response and evolved along this B cell lineage. These anti-
bodies both use the IGHV3-30*01 germline. Interestingly, this is
the same heavy-chain germline used by FI6v3, which is also
capable of neutralizing all Grp1 and Grp2 human influenza iso-
lates. Although the number of examples is too few to suggest
a trend for a common germline preference as is observed for
Grp1-specific antibodies, it is tempting to speculate that such
a preference may also exist for Grp2-specific and Grp1/2-spe-
cific antibodies.–103, July 17, 2013 ª2013 Elsevier Inc. 99
Figure 5. In Vivo Efficacy of 39.29 in Four Different InfluenzaAMouse
Infection Models
DBA/2J mice were infected with a minimum lethal dose of A/PR/8/1934 (A),
A/Port Chalmers/1/1973 (B), A/Hong Kong/8/1968 (C), or A/Aichi/2/1968 (D)
72 hr prior to i.v. administration of 39.29. Mice were monitored for body con-
ditioning, weight loss, and survival for 21 days. All 39.29 doses versus the
control in all four influenza A strain infections give a log-rank test of p < 0.01.
See also Figure S4.
Figure 6. In Vivo Efficacy of 39.29 Compared to and in Combination
with Oseltamivir
(A) Balb/Cmicewere infectedwith a high lethal dose of A/PR/8/1934 48 hr prior
to i.v. administration of 300 mg 39.29, control IgG, or oral 2 mg oseltamivir b.i.d.
for 5 days. A log-rank test of 39.29 or oseltamivir versus control gives p < 0.01,
and a maximum-likelihood test of 39.29 versus oseltamivir gives p < 0.05.
(B) Ferrets were infected with an LD90 dose of A/Vietnam/1204/2004 for 48 or
72 hr prior to the i.v. administration of 25 mg/kg 39.29, control IgG, or oral
25 mg/kg oseltamivir b.i.d. for 5 days. The log-rank test comparing the com-
bined antibody-treatment groups of 39.29 and 81.39 to all oseltamivir-treat-
ment groups gives p < 0.01.
(C) Balb/C mice were infected with a high lethal dose of A/PR/8/1934 for 72 hr
before the i.v. administration of 100 mg 39.29, control IgG, oral 2mg oseltamivir
b.i.d., or a combination of 39.29 and oseltamivir. A log-rank test of the com-
bination treatment versus 39.29 or oseltamivir gives p < 0.01.
See also Figure S5.
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izing antibody sequences described in this report probably
reflects accumulation of somatic mutation following repeated
exposure to HA. It was previously shown that just seven muta-
tions were required for maturing CR6261 into a potent Grp1-
specific neutralizing mAb (Lingwood et al., 2012). It may be100 Cell Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inhypothesized that a higher number of somatic mutations would
be required for generating a potent Grp1/2-specific antibody.
However, this may not be the case, because 39.29 and
81.39 do not contain an excessive number of somatic muta-
tions compared to what is observed for CR6261. This would
suggest that driving germline usage and preferentially expand-
ing these B cell lineages are more important for generating
a robust Grp1/2 neutralization response than generating
excessively high numbers of somatic mutations within other
germlines. This observation should be considered whilec.
Cell Host & Microbe
Enrichment Technique for Influenza Antibodiesinvestigating the effectiveness of future universal influenza vac-
cine candidates.
The comparison of the 39.29 and FI6v3 HA crystal structures
suggests that there are multiple ways by which Grp1/2-neutral-
izing antibodies can engage this highly conserved HA-stalk
epitope. Interestingly, the FI6v3 and 39.29 antibodies both use
light-chain contacts to bind the HA stalk epitope (Figure 4).
This is in contrast to the phage-display influenza antibodies,
which typically do not have light-chain contacts and are also un-
able to bind this epitope across all Grp1 and Grp2 human HA
subtypes. These data suggest that light-chain contacts are
important for the ability of these antibodies to bind and neutralize
all Grp1 and Grp2 human influenza A isolates, which under-
scores the necessity of developing proper heavy- and light-chain
pairing when attempting to discover rare functional antibodies
for influenza A.
The 39.29 mAb synergizes with the treatment of oseltamivir in
a mouse infection model, such that coadministration has signif-
icant advantages over oseltamivir treatment alone. This report
shows a profound in vivo advantage of combining antibody
and oseltamivir treatments. This dramatic in vivo effect is prob-
ably due to the distinct mode of action for 39.29, which blocks
viral infectivity, versus the mode of action for oseltamivir, which
disrupts viral budding. Therefore, blocking two critical steps in
the influenza A life cycle may have added benefit for severely in-
fected, hospitalized patients. Alternatively, oseltamivir treatment
may result in higher levels of HA expression on the surface of
infected epithelial cells, allowing greater efficiency of 39.29 in
targeting these cells for antibody-dependent cell-mediated cyto-
toxicity (ADCC). Future studies will be necessary for understand-
ing the exact mechanism by which oseltamivir and 39.29
synergize.
The enrichment technique described here has yielded two
influenza A antibodies with potential clinical significance. In clos-
ing, we believe this enrichment technique can be used to
discover rare functional antibodies for additional infectious-dis-
ease targets. For example, IgG cloning of B cells from HIV-
infected patients with broadly neutralizing serum has yielded
some very potent antibodies (Wu et al., 2010; Pejchal et al.,
2011; Walker et al., 2011). It is probable that the immune reper-
toire of these individuals has just begun to be appreciated and
that this technique could be used to enrich, expand, anddiscover
additional antibodies that have a greater breadth of potency.
EXPERIMENTAL PROCEDURES
Ethics Statements
Leukopac or blood from healthy human donors was obtained after written
informed consent was provided and ethical approval was granted by theWest-
ern Institutional Review Board. All animals used in this study were housed and
maintained at Genentech in accordance with American Association of Labora-
tory Animal Care guidelines. All experimental studies were conducted under
protocols approved by the Institutional Animal Care and Use Committee of
Genentech Lab Animal Research in an Association for Assessment and
Accreditation of Laboratory Animal Care International-accredited facility in
accordance with the Guide for the Care and Use of Laboratory Animals and
applicable laws and regulations.
hSCID Chimeras and In Vivo Plasmablast Expansion
Leukopaks from normal human donors that received the Fluvirin seasonal
influenza vaccine (Novartis lot no. 111796P1) or the TD vaccine 7 days priorCellto their blood donation were obtained from Blood Centers of the Pacific,
and PBMCs were isolated using standard Ficoll cell-separation metho-
dologies. PBMCs were resuspended with influenza A HA or TT antigens
at 1 mg for 1 million B cells and incubated for 30 min at 37C. Cells were
washed in sterile saline after premix and reconstituted for intrasplenic
injections. Antigens used in this study include Tetanus toxoid (List Biological
Laboratories) and H1 HA from A/WSN/1933, H3 HA from A/Hong Kong/8/
1968, and H7 HA from A/Netherlands/219/2003 produced at Genentech.
The 6- to 8-week-old female SCID/beige mice were purchased from Charles
River Laboratories and housed and maintained at Genentech in accordance
with American Association of Laboratory Animal Care guidelines. SCID/beige
mice were sublethally irradiated with 350 rads using a Cesium-137 source.
Polymyxin B (110 mg/l) and neomycin (1.1 g/l) were added to the drinking
water for 7 days after irradiation. Four hours after irradiation, the left flank
of each mouse was shaved and prepped with Betadine (Purdue Pharma)
and 70% alcohol. The operation was performed under anesthesia using
aseptic surgical procedures. A 1 cm skin incision was made just below
the costal border, followed by an incision of the abdominal wall and
the peritoneum. The spleen was carefully exposed and injected with 50 3
106 hPBMCs in 30 ml PBS. The incisions were closed in the muscular layer
and the skin with 5-O VICRYL sutures (Ethicon) and surgical staples, re-
spectively. For antigen-specific cell sorting, mice were sacrificed at 8 days
posttransplantation, and spleens were harvested and processed for flow-
cytometry analysis. For comparing the in vivo enrichment conditions, 50 3
106 PBMCs from normal human donors that received the TD vaccine
7 days prior to their blood donation were injected intrasplenically into
SCID/beige recipients. Mice in groups of n = 7 were subjected to the
following stimulation conditions: ‘‘cells only,’’ wherein there was no additional
stimulation; and ‘‘cytokines,’’ wherein mice received intraperitoneal injections
of cytokine cocktails containing a mixture of human BAFF (50 mg) and human
IL-2, IL-6, and IL-21 at 50 ng each on days 1, 4, and 7 after transplantation.
The in vivo boost contained 100 mg TT injected intraperitoneally into hSCID
mice on day 2 after transplantation. Antigen premix, as detailed in Results,
contained a 30 min in vitro incubation of antigen and PBMCs, followed by
a wash of excess antigen prior to transplantation. On day 8 post transplan-
tation, mice were sacrificed and splenocytes were processed for intracellular
IgG and antigen-specific plasmablast staining by flow cytometry. For influ-
enza HA antigen premix effect confirmation, 50 3 106 PBMCs from normal
human donors that received the Fluvirin seasonal vaccine 7 days prior to
their blood donation were injected intrasplenically into SCID/beige recipients.
Groups of 10 or 30 mice were either subjected to the HA antigen premix, as
detailed in Results, or injected with cells alone (no antigen premix). On day 8
post transplantation, mice were sacrificed and splenocytes were processed
for intracellular IgG and antigen-specific plasmablast staining by flow
cytometry.
Flow Cytometry and Cell Sorting
Spleen single-cell suspensions were stained with surface human mAbs
(CD38 PECy7, BD Biosciences) and cytoplasmic IgG DyLight (Jackson
ImmunoResearch Laboratories), which define human IgG+ plasmablasts as
CD38hiIgG+. For TT antigen enrichment studies, cytoplasmic rTTc.PE (List
Biological Laboratories) was added in the cocktail to identify TT+IgG+ plas-
mablasts. For influenza HA antigen enrichment studies, intracellular HA anti-
gens, H1 from A/WSN/1933 and H3 from A/Hong Kong/8/1968, which were
conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE),
respectively, using Lightning-Link labeling kits (Innova Biosciences), were
added to the staining cocktail. For identification of HA cross-reactive plasma-
blasts for cell-sorting purposes, cells were stained with surface human mAbs
(CD38 PECy7, BD Biosciences), IgG DyLight (Jackson ImmunoResearch
Laboratories), and H1 from A/WSN/1933 and H3 from A/Hong Kong/8/
1968, which were conjugated with FITC or PE, respectively, using Light-
ning-Link labeling kits. Samples were analyzed in the presence of propidium
iodide dead-cell exclusion on an Aria high-speed cell sorter (BD Biosciences),
and antigen-specific plasmablasts were sorted in a single-cell manner into
96-well tissue-culture plates containing 50 ml of RPMI media supplemented
with 5% fetal bovine serum (FBS). Five million live cells were recorded from
the sort profiles for subsequent analysis purposes. Profiles were analyzed
by FlowJo v.9.4.11 software.Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inc. 101
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DBA/2J mice (Jackson Laboratory) were infected intranasally with 50 ml of
different influenza A strains diluted into influenza media (Dulbecco’s modified
Eagle’s medium, +0.2% BSA, +2 mg/ml TPCK-treated trypsin) at the minimum
lethal dose 100% (LD100). H1N1 A/PR/8/1934 (Genentech) was used at 80
plaque-forming units (pfu) per mouse. The H3N2 A/Hong Kong/1/1968 (VIRA-
PUR) was dosed at 3 pfu per mouse. The H3N2 A/Port Chalmers/1/1973
(VIRAPUR) was dosed at 1.2 3 104 pfu per mouse. The H3N2 A/Aichi/2/
1968 (VIRAPUR) was dosed at 2 3 102 pfu per mouse. At either 48 or 72 hr
post infection, HA antibody 39.29 was administered i.v. at 900 mg/mouse
(roughly 45 kg/mg), 300 mg/mouse (roughly 15 kg/mg), or 100 mg/mouse
(roughly 5 kg/mg) in 200 ml PBS. Control-treated animals were given mAb
gD5237, which is specific for glycoprotein D of herpes simplex virus (HSV) at
the highest tested equivalent dose of 39.29 (Genentech). Mice were monitored
for body conditioning and survival until 21 days after infection.
The ferret H5N1 study was completed under contract at the Lovelace Res-
piratory Research Institute (Albuquerque, NM, USA). Male ferrets (Mustela pu-
torius furo) were challenged with an intranasal dose of 13 103 pfu of the highly
virulent H5N1 A/Vietnam/1203/2004 influenza A strain. Animals were infected
48 or 72 hr prior to receiving antibody i.v. or Tamiflu by oral gavage. The con-
trol-treated animals received a 25 mg/kg i.v. dose of the mAB, gD5237, spe-
cific for glycoprotein D of HSV. The anti-influenza-treated animals received a
single 25 mg/kg i.v. dose of either 39.29 or 81.39 at 48 or 72 hr post infection.
The oseltamivir phosphate was purchased from Toronto Research Chemicals
(cat. no. O701000). The oseltamivir-treated animals received a twice-daily oral
dose of 25 mg/kg for 5 days. Animals were monitored daily for weight loss, fe-
ver, body conditioning, and survival.
For the severe mouse influenza infection models to compare the effective-
ness of oseltamivir to antibody treatment or to test the combination of antibody
and oseltamivir, 6-7 week old female Balb/C mice (Charles River Laboratories)
were infected with 5x104 pfu of A/PR/8/1934. Oseltamivir treated mice were
given 2 mg/mouse orally twice a day for 5 days beginning at either 48 or
72 hr post infection. Mice receiving 39.29 were given a single 100 mg or
300 mg IV dose at either 48 or 72 hr post infection.
IgG Cloning from Single Plasmablasts
Single plasmablasts were sorted directly into U-bottom 96-well microwell
plates containing 50 ml of RPMI with 5% low IgG FBS (Gibco). Plates were
centrifuged for 5 min at 600 3 g (Beckman Coulter), and the media was care-
fully removed by aspiration. The cells were resuspended and washed twice in
90 ml of PBS following the same procedure. To generate complementary DNA
(cDNA) encoding the variable heavy and light chains, each cell was resus-
pended in 6 ml of a reverse transcriptase (RT) reaction mixture comprised of
2 units of RNaseOUT (Invitrogen), 0.5 mM 4 dinucleotide triphosphate
(dNTP; PerkinElmer), 1.5 mM MgCl2, 37.5 mM KCl, 10 mM dithiothreitol
(DTT), 0.25% Nonidet P40 (US Biological), 0.1 mg/ml BSA (Sigma-Aldrich),
25 mM Tris (pH 8.3), 0.25 pmol of IgG1–4, k chain and l chain constant-re-
gion-specific oligonucleotides (Table S2), and 40 U SuperScript III (Invitrogen).
The reaction was incubated for 30 min intervals at 45, 50, and 55C. The IgG
heavy and light chains were PCR amplified and cloned into mammalian
expression vectors for transient production. See Supplemental Experimental
Procedures for the detailed cloning protocol.
Structure Determination
The structure has been deposited and can be accessed using the Protein Data
Bank (PDB) ID code 4KVN. Initial phases were obtained by molecular replace-
ment with Phaser (McCoy et al., 2007) using the structure of an H3 HA (PDB
code 3SDY) as a search model. Subsequently, the Fc and Fv portions of the
Fab were placed separately using Phaser and underwent initial rounds of
rigid-body refinement with Phenix (Adams et al., 2010). The model went
through several iterative rounds of adjustment with Coot (Emsley and Cowtan,
2004) and simulated annealing, coordinate, and B-factor refinement with Phe-
nix. Sugar molecules found at Asn-linked glycosylation sites were added using
the CarboLoad package from Phenix, and final rounds of refinement were car-
ried out using REFMAC5 (Murshudov et al., 1997) and BUSTER (Global
Phasing). The final model was refined at 3.1 A˚ with R and Rfree values of
20.5% and 24.8%, respectively (Table S5). Ramachandran statistics calcu-
lated by MolProbity (Chen et al., 2010) indicate that 93.7% of the residues102 Cell Host & Microbe 14, 93–103, July 17, 2013 ª2013 Elsevier Inlie in favored regions, and 0.6% are outliers. Contacts were analyzed using
the PDBePISA (Protein Interfaces, Surfaces, and Assemblies) software (Krissi-
nel and Henrick, 2007), and structural figures were prepared with PyMOL
(Schro¨dinger, LLC). A detailed explanation of the protein purification and crys-
tallization conditions can be found in the Supplemental Experimental
Procedures.
Statistical Analyses
Statistics were calculated using JMP v.9.0.2 software (SAS Institute). We
compared survival using a log-rank test. p values <0.05 were considered sig-
nificant. IC50 curves and values were plotted and calculated using GraphPad
Prism v.5.0 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2013.06.004.
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